.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,613,950

« Back to Dashboard
Patent 8,613,950 protects STAXYN and is included in one NDA. There has been one Paragraph IV challenge on Staxyn. There are three tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

This patent has forty-four patent family members in thirty-six countries.

Summary for Patent: 8,613,950

Title:Pharmaceutical forms with improved pharmacokinetic properties
Abstract: The present application relates to novel drug formulations of vardenafil which dissolve rapidly in the mouth and lead to increased bioavailability and to a plateau-like plasma concentration profile, and to processes for their preparation.
Inventor(s): Serno; Peter (Gladbach, DE), Heinig; Roland (Wuppertal, DE), Pauli; Kerstin (Dortmund, DE), Hayauchi; Yutaka (Leverkusen, DE)
Assignee: Bayer Intellectual Property GmbH (Monheim, DE)
Application Number:11/885,019
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Device;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 0th percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Bayer Hlthcare
STAXYN
vardenafil hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL200179-001Jun 17, 2010RXYes8,613,950► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,613,950

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany10 2005 009 240Mar 1, 2005
PCT Information
PCT FiledFebruary 16, 2006PCT Application Number:PCT/EP2006/001393
PCT Publication Date:September 08, 2006PCT Publication Number: WO2006/092207

International Patent Family for Patent: 8,613,950

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Spain2384109► subscribe
Guatemala200600097► subscribe
Hong Kong1118457► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc